Future experiments, such as gene editing, which utilise the pharmacologically reversible loss of function mutations at positions TM2.6 and TM4.6 of TREK channels described here, will help to clarify the importance of TREK channels in pathophysiological conditions such as pain and depression. The gene discussed is KCNK2; the disease is depressive disorder.